SCHEMBL7100010

SCHEMBL7100010

FC(F)(F)c1cccc(C2=CCNC(CCc3ccc4ccccc4c3)C2)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.43
OPRL1 P41146 1/20 0.37
MAOB P27338 2/20 0.36
HRH1 P35367 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
CXCR2 P25025 1/20 0.35
CXCR3 P49682 1/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
HTR7 P34969 1/20 0.33
S1PR5 Q9H228 1/20 0.33
SCN2A Q99250 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
DRD4 P21917 1/20 0.32
ROCK1 Q13464 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1742023 0.99 HTR2C (0.44) HTR2COPRL1MAOBHRH1HRH4
SCHEMBL7439313 0.88 MAOB (0.46) HTR2CMAOBHRH1HRH4CXCR2
SCHEMBL8540798 0.87 HTR2C (0.44) HTR2CMAOBHRH1HRH4CXCR2
SCHEMBL7453648 0.84 HTR2C (0.40) HTR2CMAOBHRH1HRH4CXCR2
SCHEMBL8024707 0.84 HTR2C (0.41) HTR2CMAOBHRH1HRH4CXCR3
SCHEMBL7454616 0.83 HTR2C (0.41) HTR2CMAOBHRH1HRH4CXCR3
SCHEMBL8541203 0.82 HTR2C (0.42) HTR2CMAOBHRH1HRH4CXCR3
SCHEMBL8542783 0.82 MAOB (0.42) HTR2CMAOBHRH1HRH4CXCR3
SCHEMBL8543404 0.81 FAAH (0.42) HTR2CMAOBHRH1HRH4
SCHEMBL8541412 0.81 HTR2C (0.39) HTR2CMAOBHRH1HRH4CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0866704-B1 USE OF 1-(2-NAPHTH-2-YLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE FOR PREPARING DRUGS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SANOFI SYNTHELABO (FR) 2001-04-11 EP claimed
EP-0950050-A1 METHOD FOR THE CRYSTALLISATION OF A TETRAHYDOPYRIDIN DERIVATIVE AND RESULTING CRYSTALLINE FORMS SANOFI-SYNTHELABO (FR) 1999-10-20 EP claimed
EP-0866704-A1 USE OF 1-(2-NAPHTH-2-YLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE FOR PREPARING DRUGS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SANOFI (FR) 1998-09-30 EP claimed
WO-1998028271-A1 METHOD FOR THE CRYSTALLISATION OF A TETRAHYDOPYRIDIN DERIVATIVE AND RESULTING CRYSTALLINE FORMS SANOFI (FR) 1998-07-02 WO claimed
WO-1997015304-A1 USE OF 1-(2-NAPHTH-2-YLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE FOR PREPARING DRUGS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SANOFI (FR) 1997-05-01 WO claimed
EP-0950051-B1 MICRO-PARTICULATE FORM OF A TETRAHYDROPYRIDIN DERIVATIVE SANOFI SYNTHELABO (FR) 2003-09-17 EP disclosed
EP-1102586-A1 USE OF GINKGO BILOBA EXTRACTS FOR PREPARING A MEDICINE FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2001-05-30 EP disclosed
EP-1017385-A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 SANOFI-SYNTHELABO (FR) 2000-07-12 EP disclosed
WO-2000007592-A1 USE OF GINKGO BILOBA EXTRACTS FOR PREPARING A MEDICINE FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2000-02-17 WO disclosed
EP-0979079-A1 USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION SANOFI-SYNTHELABO (FR) 2000-02-16 EP disclosed
EP-0950051-A1 MICRO-PARTICULATE FORM OF A TETRAHYDROPYRIDIN DERIVATIVE SANOFI-SYNTHELABO (FR) 1999-10-20 EP disclosed
EP-0950052-A1 METHOD FOR PREPARING A TETRAHYDROPYRIDIN DERIVATIVE SANOFI-SYNTHELABO (FR) 1999-10-20 EP disclosed
WO-1998053821-A1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 SANOFI-SYNTHELABO (FR) 1998-12-03 WO disclosed
WO-1998048802-A1 USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION SANOFI-SYNTHELABO (FR) 1998-11-05 WO disclosed
EP-0866704-A1 USE OF 1-(2-NAPHTH-2-YLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE FOR PREPARING DRUGS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SANOFI (FR) 1998-09-30 EP disclosed
WO-1998028273-A1 METHOD FOR PREPARING A TETRAHYDROPYRIDIN DERIVATIVE SANOFI (FR) 1998-07-02 WO disclosed
WO-1998028272-A1 MICRO-PARTICULATE FORM OF A TETRAHYDROPYRIDIN DERIVATIVE SANOFI (FR) 1998-07-02 WO disclosed
WO-1997015304-A1 USE OF 1-(2-NAPHTH-2-YLETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE FOR PREPARING DRUGS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS SANOFI (FR) 1997-05-01 WO disclosed
US-5026716-A Method of treatment of anxiety and anxio-depressive disorders SANOFI (FR) 1991-06-25 US disclosed